Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Relapsed or Refractory Mantle Cell Lymphoma
Clinical trial NCT02169180 · COMPLETED
Trial details
- NCT number
- NCT02169180
- Sponsor
- Janssen Pharmaceutical K.K.
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2014-08-01
- Primary completion
- 2016-11-01
- Enrollment
- 16
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.